Tag
Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting
A novel curcumin-based polymer prodrug nanoplatform enhances immunotherapy in head and neck cancer by targeting tumor cell stemness and reversing immunosuppression via synergistic photothermal, photodynamic, and ferroptosis mechanisms.
The TrilynX phase III study showed that adding xevinapant to platinum-based chemoradiotherapy did not improve event-free survival and was associated with worse overall survival and higher toxicity in unresected locally advanced squamous cel
The phase 3 KEYNOTE-689 trial demonstrates that adding perioperative pembrolizumab to surgery and adjuvant therapy significantly improves event-free survival in locally advanced HNSCC without compromising surgical outcomes or safety.
The UPGRADE-RT multicenter trial confirms that lowering elective neck irradiation dose in definitive radiotherapy for head and neck cancer maintains disease control and improves quality of life, reducing toxicity without increasing recurren
A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.
